Clear. 65.3   F New York
AI-Powered News Summarizer
Top Stories

Coronavirus vaccines: 'Encouraging' early data for some, a trial delay for another and more research ahead

July 2, 2020. Summarized by summa-bot.

Scientists around the world are racing to develop Covid-19 vaccines and there's news almost daily about steps forward -- this week, there was "encouraging" preliminary data for some vaccine candidates and word from top health officials that the United States could be on track to have a vaccine by the end of the year.

(CNN)Scientists around the world are racing to develop Covid-19 vaccines and there's news almost daily about steps forward -- this week, there was "encouraging" preliminary data for some vaccine candidates and word from top health officials that the United States could be on track to have a vaccine by the end of the year.

Researchers at University of Oxford said this week they have vaccinated 8,000 people in the UK as part of a Phase 3 trial.

On Thursday, an investigator working on the Moderna vaccine candidate said the company's Phase 3 trial -- expected to be the first in the United States -- will likely start at the end of the month or the beginning of August, later than had been expected.

After the delay was reported in STAT, Moderna said on Twitter it "has previously disclosed that the Phase 3 trial of its COVID-19 vaccine candidate MRNA-1273 is expected to begin in July.

Another Covid-19 vaccine candidate being developed by US pharmaceutical company Pfizer and German biotechnology company BioNTech yielded positive data in early tests, according to data released by the companies this week.

Pfizer and BioNTech announced on Wednesday that this preliminary data will help them determine a dose level for the vaccine then select which of their multiple vaccine candidates to progress to a larger-scale global Phase 2/3 study, possibly beginning as early as this month.

US vaccine maker Inovio said on Tuesday that its coronavirus vaccine already has shown some positive early data in a Phase 1 trial.

The company said that 94% of people in the Phase 1 trial demonstrated overall immune responses by six weeks after receiving two doses of the vaccine INO-4800 and by eight weeks, the vaccine regimen was found to be safe and well-tolerated with no serious reactions.

The company said that its vaccine is among those selected to be part of the US government's Operation Warp Speed, a national program aimed at delivering a Covid-19 vaccine to the nation by next year.

by summa-bot

Summarizer is now on Google News and Telegram. Now you can get the latest AI summarized news on your favorite platform.

Don't like these above? We have an RSS Feed for you.

Suggestions